Trials / Active Not Recruiting
Active Not RecruitingNCT04155749
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Kite, A Gilead Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anitocabtagene-autoleucel | Chimeric Antigen Receptor T cells |
Timeline
- Start date
- 2019-12-23
- Primary completion
- 2024-10-03
- Completion
- 2027-05-01
- First posted
- 2019-11-07
- Last updated
- 2026-02-11
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04155749. Inclusion in this directory is not an endorsement.